Investigators from U.S. Army Medical Research Institute of Chemical Defense Target U.S. Military Medical Research (Seizure Suppression and Neuroprotection In Soman-exposed Rats Following Delayed Intramuscular Treatment of Adenosine A1 Receptor...).

A recent study conducted by the U.S. Army Medical Research Institute of Chemical Defense has investigated the use of an adenosine A1 receptor agonist, ENBA, as a potential treatment for seizures and neuroprotection in rats exposed to the nerve agent soman. The researchers found that delayed treatment with ENBA, in combination with standard medical countermeasures, resulted in the termination of seizures and reduced neuropathology in the rats. However, the study also noted a potential reduction in survival rates with the combined treatment, suggesting the need for further adjustments in the dosage of ENBA. This research provides promising insights into the use of ENBA as an adjunct therapy for soman exposure. [Extracted from the article]